Mucosolvan (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Mucosolvan, is a mucolytic presented as an oral formulation for oral use. It helps reduce the viscosity of bronchial secretions and is used to manage cough with thick sputum in adults and children. GNH USA supplies Mucosolvan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mucosolvan is a mucolytic that acts on respiratory conditions characterized by thick or excessive mucus. - Cough with thick or viscous sputum: loosens mucus to facilitate expectoration and improve cough effectiveness. - Acute bronchitis: reduces mucus viscosity, aiding clearance and symptom relief. - Chronic bronchitis: assists in regular mucus clearance, helping to manage chronic productive cough. - Chronic obstructive pulmonary disease (COPD): supports mucus clearance to ease breathing difficulties. - Asthma with mucus hypersecretion: helps clear airway secretions, complementing other asthma therapies.

Mucosolvan is generally well tolerated, but some patients may experience adverse reactions.

Common Side Effects: - Nausea: mild stomach upset after oral intake. - Diarrhea: loose stools occurring shortly after dosing. - Skin rash: localized erythema or itching. - Taste disturbance: temporary alteration of taste perception.

Serious or Rare Side Effects: - Allergic reaction: hives, swelling, or difficulty breathing. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: abnormal liver enzyme elevations. - Hematologic changes: rare cases of blood cell count alterations.

Before using Mucosolvan, consider the following precautions. - Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: discuss potential risks with a physician. - Pediatric use: follow prescriber guidance for children; dosage is age‑dependent. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant respiratory conditions: monitor response in asthma or COPD patients. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Mucosolvan may interact with other medicines; awareness of potential interactions is important.

Major Interactions (Avoid): - Anticholinergic agents: may reduce mucociliary clearance, diminishing therapeutic effect. - Highly protein‑bound drugs: potential displacement leading to altered plasma levels.

Moderate Interactions (Monitor Closely): - Bronchodilators (e.g., beta‑agonists): monitor for additive cough suppression. - Antibiotics for respiratory infections: assess for synergistic effects on mucus clearance. - Antihistamines: may increase risk of dry mouth or throat irritation.